{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T01:40:32Z","timestamp":1783388432106,"version":"3.54.6"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.japh.2019.12.004","type":"journal-article","created":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T13:59:52Z","timestamp":1578923992000},"page":"462-469.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Potential cost savings by prevention of adverse drug events with a novel medication review program"],"prefix":"10.1016","volume":"60","author":[{"given":"Elena V.","family":"Fern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy L.","family":"Warriner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tosin","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Twigg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman V.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.japh.2019.12.004_bib1","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1136\/qshc.2004.010611","article-title":"Adverse drug events and medication errors: detection and classification methods","volume":"13","author":"Morimoto","year":"2004","journal-title":"Qual Saf Health Care"},{"key":"10.1016\/j.japh.2019.12.004_bib2","article-title":"30-day potentially avoidable readmissions due to adverse drug events [e-pub ahead of print]","author":"Dalleur","year":"2017","journal-title":"J\u00a0Patient Saf"},{"issue":"1","key":"10.1016\/j.japh.2019.12.004_bib3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11606-009-1141-3","article-title":"Adverse drug event rates in six community hospitals and the potential impact of computerized physician order entry for prevention","volume":"25","author":"Hug","year":"2010","journal-title":"J\u00a0Gen Intern Med"},{"issue":"1","key":"10.1016\/j.japh.2019.12.004_bib4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jama.1995.03530010043033","article-title":"Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE prevention study group","volume":"274","author":"Bates","year":"1995","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.japh.2019.12.004_bib5","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s00228-017-2330-3","article-title":"The prevalence of medication-related adverse events in inpatients\u2013a systematic review and meta-analysis","volume":"73","author":"Laatikainen","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.japh.2019.12.004_bib6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00228-017-2373-5","article-title":"Categorization and association analysis of risk factors for adverse drug events","volume":"74","author":"Zhou","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.japh.2019.12.004_bib7","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1001\/jama.1997.03540280045032","article-title":"The costs of adverse drug events in hospitalized patients. Adverse drug events prevention study group","volume":"277","author":"Bates","year":"1997","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.japh.2019.12.004_bib8","first-page":"120","article-title":"The costs of adverse drug events in community hospitals","volume":"38","author":"Hug","year":"2012","journal-title":"Jt Comm J Qual Patient Saf"},{"issue":"8","key":"10.1016\/j.japh.2019.12.004_bib9","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2146\/ajhp090056","article-title":"Effects of an adverse-drug-event alert system on cost and quality outcomes in community hospitals","volume":"67","author":"Piontek","year":"2010","journal-title":"Am J Health Syst Pharm"},{"issue":"3","key":"10.1016\/j.japh.2019.12.004_bib10","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1136\/qshc.2004.010942","article-title":"Medication safety program reduces adverse drug events in a community hospital","volume":"14","author":"Cohen","year":"2005","journal-title":"Qual Saf Health Care"},{"issue":"6","key":"10.1016\/j.japh.2019.12.004_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2014.08.063","article-title":"An internal quality improvement collaborative significantly reduces hospital-wide medication error related adverse drug events","volume":"165","author":"McClead","year":"2014","journal-title":"J\u00a0Pediatr"},{"issue":"8","key":"10.1016\/j.japh.2019.12.004_bib12","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/j.1532-5415.2004.52367.x","article-title":"Risk factors for adverse drug events among older adults in the ambulatory setting","volume":"52","author":"Field","year":"2004","journal-title":"J\u00a0Am Geriatr Soc"},{"issue":"7-8","key":"10.1016\/j.japh.2019.12.004_bib13","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1345\/aph.1P627","article-title":"Prevalence of adverse drug events in ambulatory care: a systematic review","volume":"45","author":"Tach\u00e9","year":"2011","journal-title":"Ann Pharmacother"},{"issue":"9","key":"10.1016\/j.japh.2019.12.004_bib14","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1001\/jama.289.9.1107","article-title":"Incidence and preventability of adverse drug events among older persons in the ambulatory setting","volume":"289","author":"Gurwitz","year":"2003","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.japh.2019.12.004_bib15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/PTS.0b013e3181dcae06","article-title":"Outpatient adverse drug events identified by screening electronic health records","volume":"6","author":"Gandhi","year":"2010","journal-title":"J\u00a0Patient Saf"},{"issue":"12","key":"10.1016\/j.japh.2019.12.004_bib16","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1097\/01.mlr.0000185690.10336.70","article-title":"The costs associated with adverse drug events among older adults in the ambulatory setting","volume":"43","author":"Field","year":"2005","journal-title":"Med Care"},{"issue":"2","key":"10.1016\/j.japh.2019.12.004_bib17","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1331\/108658003321480713","article-title":"The Asheville project: long-term clinical and economic outcomes of a community pharmacy diabetes care program","volume":"43","author":"Cranor","year":"2003","journal-title":"J\u00a0Am Pharm Assoc (Wash)"},{"issue":"2","key":"10.1016\/j.japh.2019.12.004_bib18","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3390\/pharmacy7020066","article-title":"An improved comprehensive medication review process to assess healthcare outcomes in a rural independent community pharmacy","volume":"7","author":"Twigg","year":"2019","journal-title":"Pharmacy (Basel)"},{"issue":"1","key":"10.1016\/j.japh.2019.12.004_bib19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.20982\/tqmp.08.1.p023","article-title":"Computing inter-rater reliability for observational data: an overview and tutorial","volume":"8","author":"Hallgren","year":"2012","journal-title":"Tutor Quant Methods Psychol"},{"issue":"3","key":"10.1016\/j.japh.2019.12.004_bib20","doi-asserted-by":"crossref","first-page":"276","DOI":"10.11613\/BM.2012.031","article-title":"Interrater reliability: the kappa statistic","volume":"22","author":"McHugh","year":"2012","journal-title":"Biochem Med (Zagreb)"},{"issue":"3","key":"10.1016\/j.japh.2019.12.004_bib21","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1067\/mem.2002.121401","article-title":"Adverse drug events in emergency department patients","volume":"39","author":"Hafner","year":"2002","journal-title":"Ann Emerg Med"},{"issue":"3","key":"10.1016\/j.japh.2019.12.004_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.annemergmed.2011.01.003","article-title":"Outcomes of emergency department patients presenting with adverse drug events","volume":"58","author":"Hohl","year":"2011","journal-title":"Ann Emerg Med"},{"issue":"16","key":"10.1016\/j.japh.2019.12.004_bib23","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1056\/NEJMsa020703","article-title":"Adverse drug events in ambulatory care","volume":"348","author":"Gandhi","year":"2003","journal-title":"N\u00a0Engl J Med"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319119305436?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319119305436?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:46:33Z","timestamp":1761543993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319119305436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S1544319119305436"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2019.12.004","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential cost savings by prevention of adverse drug events with a novel medication review program","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2019.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}